These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
491 related articles for article (PubMed ID: 17108865)
1. Treatment of irritable bowel syndrome. A case control experience. Astegiano M; Pellicano R; Terzi E; Simondi D; Rizzetto M Minerva Gastroenterol Dietol; 2006 Dec; 52(4):359-63. PubMed ID: 17108865 [TBL] [Abstract][Full Text] [Related]
2. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995 [TBL] [Abstract][Full Text] [Related]
3. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Drouault-Holowacz S; Bieuvelet S; Burckel A; Cazaubiel M; Dray X; Marteau P Gastroenterol Clin Biol; 2008 Feb; 32(2):147-52. PubMed ID: 18387426 [TBL] [Abstract][Full Text] [Related]
4. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Colecchia A; Vestito A; La Rocca A; Pasqui F; Nikiforaki A; Festi D; Minerva Gastroenterol Dietol; 2006 Dec; 52(4):349-58. PubMed ID: 17108864 [TBL] [Abstract][Full Text] [Related]
5. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Tsuchiya J; Barreto R; Okura R; Kawakita S; Fesce E; Marotta F Chin J Dig Dis; 2004; 5(4):169-74. PubMed ID: 15612887 [TBL] [Abstract][Full Text] [Related]
6. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Talley NJ; Dennis EH; Schettler-Duncan VA; Lacy BE; Olden KW; Crowell MD Am J Gastroenterol; 2003 Nov; 98(11):2454-9. PubMed ID: 14638348 [TBL] [Abstract][Full Text] [Related]
7. Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome. Hertig VL; Cain KC; Jarrett ME; Burr RL; Heitkemper MM Nurs Res; 2007; 56(6):399-406. PubMed ID: 18004186 [TBL] [Abstract][Full Text] [Related]
8. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240 [TBL] [Abstract][Full Text] [Related]
9. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Zeng J; Li YQ; Zuo XL; Zhen YB; Yang J; Liu CH Aliment Pharmacol Ther; 2008 Oct; 28(8):994-1002. PubMed ID: 18671775 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Rahimi R; Nikfar S; Abdollahi M Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935 [TBL] [Abstract][Full Text] [Related]
11. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Hun L Postgrad Med; 2009 Mar; 121(2):119-24. PubMed ID: 19332970 [TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Paré P; Gray J; Lam S; Balshaw R; Khorasheh S; Barbeau M; Kelly S; McBurney CR Clin Ther; 2006 Oct; 28(10):1726-35; discussion 1710-1. PubMed ID: 17157129 [TBL] [Abstract][Full Text] [Related]
13. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Houghton LA; Lea R; Agrawal A; Reilly B; Whorwell PJ Gastroenterology; 2006 Oct; 131(4):1003-10. PubMed ID: 17030170 [TBL] [Abstract][Full Text] [Related]
14. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Leventer SM; Raudibaugh K; Frissora CL; Kassem N; Keogh JC; Phillips J; Mangel AW Aliment Pharmacol Ther; 2008 Jan; 27(2):197-206. PubMed ID: 17973974 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey]. Plassmann D; Schulte-Witte H Med Klin (Munich); 2007 Nov; 102(11):888-92. PubMed ID: 17992479 [TBL] [Abstract][Full Text] [Related]
16. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346 [TBL] [Abstract][Full Text] [Related]
17. Risk factors for irritable bowel syndrome in Turkish population: role of food allergy. Uz E; Türkay C; Aytac S; Bavbek N J Clin Gastroenterol; 2007 Apr; 41(4):380-3. PubMed ID: 17413606 [TBL] [Abstract][Full Text] [Related]
18. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Enck P; Zimmermann K; Menke G; Klosterhalfen S Z Gastroenterol; 2009 Feb; 47(2):209-14. PubMed ID: 19197823 [TBL] [Abstract][Full Text] [Related]
19. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study. Bardhan KD; Forbes A; Marsden CL; Mason T; Short G Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702 [TBL] [Abstract][Full Text] [Related]